Literature DB >> 16266984

Novel pheochromocytoma susceptibility loci identified by integrative genomics.

Patricia L M Dahia1, Ke Hao, John Rogus, Christian Colin, Miguel A G Pujana, Ken Ross, Danielle Magoffin, Neil Aronin, Alberto Cascon, César Y Hayashida, Cheng Li, Sérgio P A Toledo, Charles D Stiles.   

Abstract

Pheochromocytomas are catecholamine-secreting tumors that result from mutations of at least six different genes as components of distinct autosomal dominant disorders. However, there remain familial occurrences of pheochromocytoma without a known genetic defect. We describe here a familial pheochromocytoma syndrome consistent with digenic inheritance identified through a combination of global genomics strategies. Multipoint parametric linkage analysis revealed identical LOD scores of 2.97 for chromosome 2cen and 16p13 loci. A two-locus parametric linkage analysis produced maximum LOD score of 5.16 under a double recessive multiplicative model, suggesting that both loci are required to develop the disease. Allele-specific loss of heterozygosity (LOH) was detected only at the chromosome 2 locus in all tumors from this family, consistent with a tumor suppressor gene. Four additional pheochromocytomas with a similar genetic pattern were identified through transcription profiling and helped refine the chromosome 2 locus. High-density LOH mapping with single nucleotide polymorphism-based array identified a total of 18 of 62 pheochromocytomas with LOH within the chromosome 2 region, which further narrowed down the locus to <2 cM. This finding provides evidence for two novel susceptibility loci for pheochromocytoma and adds a recessive digenic trait to the increasingly broad genetic heterogeneity of these tumors. Similarly, complex traits may also be involved in other familial cancer syndromes.

Entities:  

Mesh:

Year:  2005        PMID: 16266984     DOI: 10.1158/0008-5472.CAN-05-1427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background.

Authors:  Lauren Fishbein; Katherine L Nathanson
Journal:  Cancer Genet       Date:  2012 Jan-Feb

Review 2.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

Review 3.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 4.  Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.

Authors:  Svenja Nölting; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

5.  Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

Authors:  Suhail K Mithani; Ian M Smith; Joseph A Califano
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

Review 6.  SDH-related pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Kathryn S King; Karel Pacak
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 7.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

8.  Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.

Authors:  Svenja Nölting; Edwin Garcia; Ghassan Alusi; Alessio Giubellino; Karel Pacak; Márta Korbonits; Ashley B Grossman
Journal:  J Mol Endocrinol       Date:  2012-07-25       Impact factor: 5.098

9.  Germline mutations in TMEM127 confer susceptibility to pheochromocytoma.

Authors:  Yuejuan Qin; Li Yao; Elizabeth E King; Kalyan Buddavarapu; Romina E Lenci; E Sandra Chocron; James D Lechleiter; Meghan Sass; Neil Aronin; Francesca Schiavi; Francesca Boaretto; Giuseppe Opocher; Rodrigo A Toledo; Sergio P A Toledo; Charles Stiles; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  Nat Genet       Date:  2010-02-14       Impact factor: 38.330

10.  The approach to the patient with paraganglioma.

Authors:  Hartmut P H Neumann; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2009-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.